Provider review
Nova Review: It Names the Pathway, the Dose and the Study — and Not the Patients
Nova writes the most specific claims in this market. It names pathways, vial concentrations, dosing times and the studies behind them, and that specificity is a gift to anyone checking, because there is no hedge to hide behind. Its tesamorelin page says the drug is "studied for visceral fat reduction", which is true. Those studies were in HIV-associated lipodystrophy, and the page does not say so once.
Names the pathway, the vial, the dose and the study — then leaves out the one detail that decides whether the study is about you.
Worth trusting if
- You want claims specific enough to check, which these are
- You want the prescribing clinicians named with credentials and a medical director identified
- You want a seller that states its compounding category and states it consistently
Be skeptical if
- You are considering tesamorelin without knowing that its evidence comes from HIV-associated lipodystrophy
- You want NAD+ from a seller that does not assert what it has not measured
- You want the third-party test results the site advertises, because none is published
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.trynova.co. A link is not a recommendation to take anything.
Provenance
What Nova actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Tesamorelin — From $464 a month including the $99 membership — by some distance the dearest thing Nova sells.
- NAD+ Injectable — From $134 a month including the $99 membership.
- Sermorelin — From $162 a month including the $99 membership.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to Nova.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Nova’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“GHRH analog studied for visceral (deep abdominal) fat reduction. Stimulates natural growth-hormone release via GHRH pathway. Bedtime dosing matches the natural overnight GH pulse. Tesamorelin is a GHRH (growth hormone-releasing hormone) analog studied for visceral (deep abdominal) fat reduction. Delivered as a subcutaneous injection at bedtime — timed to match your natural overnight GH pulse — it stimulates pituitary growth-hormone release without significantly affecting subcutaneous fat.”
Read on the Nova site, September 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00608023 — Phase 3, completed, n=263. TH9507 extension study in patients with HIV-associated lipodystrophy — the completed phase 3 record for this molecule. Of the 24 tesamorelin studies in the registry, the visceral-fat evidence sits overwhelmingly in HIV populations.
Every clause here is accurate and one thing has been left out. Tesamorelin is a GHRH analog; it does act on the pituitary; the visceral-versus-subcutaneous distinction is real and comes from the trial literature; and "studied for" is scrupulously chosen, because "approved for" would be false for anyone reading this page. What the page never says, in any of its words, is that those studies were in HIV-infected adults with lipodystrophy — checked by counting, the page contains no instance of "HIV" and none of "lipodystrophy". The approved label carries the population in its first sentence and adds an explicit limitation: it is not indicated for weight loss management. A reader arrives at a general telehealth storefront, sees real science accurately described, and has no way to learn that the people it was collected in are not them.1
NAD+ InjectableNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Restores cellular NAD+ to drive ATP production. Activates sirtuin pathways linked to DNA repair and longevity. Supports mental clarity and metabolic function. NAD+ Injectable delivers Nicotinamide Adenine Dinucleotide directly into circulation for maximum bioavailability. NAD+ is the coenzyme that fuels mitochondrial ATP production and activates sirtuin pathways linked to DNA repair and healthy aging. The injection format is the strongest delivery route.”
Read on the Nova site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. No trial has compared injected NAD+ against any other route for bioavailability or for any clinical outcome. The substantial human literature concerns ORAL PRECURSORS — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
Here the specificity that serves the tesamorelin page turns against this one. "Restores cellular NAD+", "activates sirtuin pathways", "drives ATP production" are assertions about what happens inside a person after an injection, and no completed randomized trial of injected NAD+ has measured any of them. Two further claims are comparative — "maximum bioavailability" and "the injection format is the strongest delivery route" — and a comparative claim needs a comparison. None has been published between injected NAD+ and any other route, for bioavailability or for anything else. The confident register is the problem: there is no "may" anywhere in this copy to tell a reader how much is unknown.2
SermorelinSermorelin · Compounded (503A)Claim reaches past the trials
“Stimulates your body's natural HGH production. Supports sleep quality and recovery. Sermorelin is a growth hormone-releasing peptide that stimulates your body's natural production of human growth hormone (HGH). Unlike synthetic HGH, Sermorelin works with your pituitary gland to boost hormone levels naturally, supporting improved sleep and faster recovery.”
Read on the Nova site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests sleep quality or recovery in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
The first half is right and the second half is untested, and the sentence welds them together so the join is hard to see. Sermorelin does stimulate the pituitary to release growth hormone — that is the mechanism and it is what all nineteen randomized trials measured — and the contrast drawn against introducing synthetic growth hormone is a real one. Then the same sentence continues "supporting improved sleep and faster recovery", and neither sleep nor recovery was an outcome in any of those nineteen trials.3
Dispensing chain
Who actually fills your prescription
Read the full account
Nova does not name its pharmacy, but it does something most of this market avoids: it states the compounding category, and states it consistently. Its weight-loss FAQ says "we specifically use 503A pharmacies", its general FAQ says "licensed, FDA-regulated 503A compounding pharmacies and standard pharmacies", and the Terms say "state-licensed compounding pharmacies operating under Section 503A". A census found no occurrence of 503B anywhere on the site, including in the production bundle — so this is a settled statement rather than a stray phrase, and it tells a reader which set of rules governs their preparation. Note that "FDA-regulated" is doing more work in that sentence than it should: a 503A pharmacy is regulated primarily by its state board, and its preparations are not FDA-approved. The prescribing side is named with credentials: Dr. Micah Craig, MD as medical director, board-certified in internal medicine, and Priscila Vidal, NP for hormone and wellness therapy. No provider number is published for either, so unlike some sellers in this market their credentials cannot be confirmed against the federal registry.
Read on the Nova site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Every page header carries the line "Third party tested medications delivered directly to your door", and no test result, certificate of analysis, potency figure or purity figure is published anywhere to go with it. That is a claim about testing rather than the testing itself, and it is the one place where Nova's usual specificity deserts it — the same site will tell you a vial is 5 mg/mL and a dose is 0.2 mL, and then says only that something, somewhere, was tested by someone. Its disclosure elsewhere is better than most: product pages state plainly that "FDA does not approve compounded medications" and that "benefits are based on third-party studies". The LegitScript certification is genuine and is the strongest form we found in this batch — the certificate resolves while an invented one returns an error through the same request, the alt text names the live domain, it links to LegitScript's checker, and the page's structured data asserts the certification as well.
Read on the Nova site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Nova says it is available in 49 states, everywhere except California, with "California coming soon". Some of the site has not caught up: the how-it-works page still says care comes from "professionals licensed in your state (TX & FL)", and the fallback title on the error page still describes the service as telehealth in Texas and Florida.
Read the full licensing claim
Two clinicians are named with credentials and background: Dr. Micah Craig, MD, medical director, board-certified in internal medicine, with a residency in Denver and a master's in biochemistry; and Priscila Vidal, NP, for hormone and wellness therapy, with more than twenty years' experience and nursing degrees from the University of Florida and Florida International University. Neither has a published provider number. The entity is NovaCure LLC, with a postal address in Northlake, Texas given in the arbitration opt-out clause of its Terms.
Named as outside that footprint
Read on the Nova site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Its claims are specific enough to be checked — pathways, vial concentrations, dose tiers and dosing times are all stated.
- Its tesamorelin page says "studied for" rather than "approved for", which is the accurate verb and one most sellers get wrong.
- The visceral-versus-subcutaneous fat distinction it draws for tesamorelin is real and comes from the trial literature.
Show 6 more
- Product pages state plainly that FDA does not approve compounded medications and that benefits rest on third-party studies.
- Two clinicians are named with credentials, including a board-certified medical director.
- It states its compounding category explicitly and consistently across the FAQ, the weight-loss FAQ and the Terms.
- Its LegitScript certification is genuine, names the live domain, links to the checker, and is asserted in the page's structured data.
- Its competitor price comparison carries a date, a note that details may have changed, and a statement that it is not affiliated with the brands listed.
- No FDA warning letter against NovaCure LLC or either named clinician.
- Its tesamorelin page never mentions HIV or lipodystrophy — the population every visceral-fat study was run in.
- The approved label for that molecule carries an explicit limitation the page does not repeat: it is not indicated for weight loss management.
- Its NAD+ copy asserts mechanisms — restoring cellular NAD+, activating sirtuin pathways, driving ATP production — that no completed randomized trial has measured.
Show 7 more
- It makes two comparative route claims for NAD+, "maximum bioavailability" and "the strongest delivery route", and no such comparison has been published.
- Its NAD+ copy contains no hedging language at all, so nothing signals to a reader how much of it is untested.
- Its sermorelin claim welds an accurate mechanism to sleep and recovery outcomes measured in none of the nineteen trials.
- "Third party tested" appears in every page header and no test result is published anywhere.
- No pharmacy is named, only its category.
- Neither named clinician has a published provider number, so their credentials cannot be checked against the federal registry.
- The how-it-works page still limits care to two states while the rest of the site claims forty-nine.
Verdict
The bottom line
Nova is the rare seller here whose claims are specific enough to argue with, and that is worth a lot. Use it. On tesamorelin, know before you order that the visceral-fat studies the page invokes were run in HIV-infected adults with lipodystrophy, and that the approved label says the drug is not indicated for weight loss management — neither fact appears on the page. On NAD+, read the copy as marketing rather than mechanism, because nothing in it has been measured in a trial. And if the third-party testing matters to you, ask for the certificate, because the site advertises the testing on every page and publishes none of it.
Opens www.trynova.co. A link is not a recommendation to take anything.
Specific enough to check
Most sellers in this market write in a fog of "may help support". Nova does not:
"GHRH analog studied for visceral (deep abdominal) fat reduction"
"Prescribed at 1 mg/day (0.2 mL of the 5 mg/mL vial) at bedtime"
"Activates sirtuin pathways linked to DNA repair and longevity"
That is a gift to anyone checking. There is no hedge to hide behind, so each claim either holds or it doesn't.
Full analysis — 4 more sectionsThe tesamorelin page, and the word that isn't on it · Where the specificity turns around · A warning letter that is not Nova's · "Third party tested"
The tesamorelin page, and the word that isn't on it
Start with what Nova gets right, because it is more than most manage.
"Studied for" is the accurate verb. Not "approved for" — which would be false for essentially everyone reading that page. The GHRH mechanism is correct. And the distinction it draws, reducing visceral fat "without significantly affecting subcutaneous fat", is real and comes straight from the trial literature.
Now the omission.
We counted the words on the rendered page. It contains "HIV" zero times and "lipodystrophy" zero times.
Every one of those visceral-fat studies was run in HIV-infected adults with lipodystrophy. The completed phase 3 record in the registry, NCT00608023, is titled for that population and enrolled 263 of them. 1
And the approved label, read from FDA's own drug-label database, opens like this:
"indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy"
then adds, explicitly:
"not indicated for weight loss management"
Nova files tesamorelin under "Energy + Strength" and sells it from a general telehealth storefront. A reader sees real science, accurately described, and is given no way to find out that the people it was collected in are not them.
Where the specificity turns around
The same confident register runs through the NAD+ page, and there it has nothing underneath it:
"Restores cellular NAD+ to drive ATP production"
"Activates sirtuin pathways linked to DNA repair and longevity"
"delivers Nicotinamide Adenine Dinucleotide directly into circulation for maximum bioavailability"
"The injection format is the strongest delivery route"
No completed randomized trial of injected NAD+ in humans has measured any of it. 2
The last two are worth separating out, because they are a different kind of claim. "Maximum bioavailability" and "strongest delivery route" are comparative — they say this route beats the others. No study has compared injected NAD+ against any other route, for absorption or for any clinical outcome. There is nothing to compare it to.
Notice also what is missing from that copy: there is no "may" in it anywhere. On the tesamorelin page Nova chose its verb with real care. Here it did not.
A warning letter that is not Nova's
Anyone searching FDA's warning-letter database for this company will hit something alarming, so here it is directly.
Searching "Try Nova" returns letter #716695, dated 9 September 2025, subject "Unlawful Sale of Unapproved and Misbranded Drugs", concerning a telehealth seller of compounded semaglutide. Same brand word. Same industry. Same drug class.
It is not this company. We opened the letter and counted what it names:
| Domain | Times named in the letter | |---|---| | trynovamd.com | 3 | | trynova.co | 0 |
Its recipient block reads "Try Nova / https://trynovamd.com", and the body says FDA reviewed website content "at the internet address https://trynovamd.com". That is a different domain and a different operator. Searches for NovaCure LLC and for both named clinicians returned nothing at all.
"Third party tested"
That phrase sits in the header of every page on the site.
No certificate of analysis, potency result or purity result is published anywhere.
It is the one place Nova's habit of specificity deserts it. The same company will tell you the vial is 5 mg/mL and the dose is 0.2 mL, and then says only that something was tested, by someone, at some point.
Questions
Frequently asked questions
Does Nova have an FDA warning letter?
No FDA warning letter. Searching for "Try Nova" does return one — letter #716695 from September 2025, about a telehealth seller of compounded semaglutide — and it belongs to a different company. We opened it: it names trynovamd.com three times and trynova.co not once, and its recipient block gives that other domain and its email address. Searches for NovaCure LLC and for both named clinicians came back empty.
Is tesamorelin proven to reduce belly fat?
In HIV-infected adults with lipodystrophy, yes — that is the approved indication and the population of the completed phase 3 trial. Nova's page describes the science accurately and never mentions that population; we counted, and the page contains no instance of "HIV" or "lipodystrophy". The approved label also states explicitly that the drug is not indicated for weight loss management. Neither fact is on the page.
Is injected NAD+ better absorbed than other forms?
Nobody has published a comparison, so the claim cannot be supported either way. "Maximum bioavailability" and "the strongest delivery route" are comparative claims, and no study has compared injected NAD+ against any other route for absorption or for any clinical outcome. There is no completed randomized trial of injected NAD+ in humans at all.
What does "third party tested" mean here?
The site does not say, and publishes no result. The phrase appears in the header of every page; no certificate of analysis, potency figure or purity figure appears anywhere. If the testing matters to you, ask for the certificate before ordering.
Which pharmacy compounds these?
Nova does not name one, but it does state the category and states it consistently — 503A, in its FAQ, its weight-loss FAQ and its Terms, with no mention of 503B anywhere on the site. That tells you which rules govern your preparation, which is more than most sellers here disclose. One caution on the wording: a 503A pharmacy is regulated primarily by its state board, and its preparations are not FDA-approved.
Is Nova available in my state?
It says 49 states — everywhere except California, with California listed as coming soon. Parts of the site have not caught up: the how-it-works page still says care comes from providers licensed in Texas and Florida.
Glossary
Key terms
Show definitions
- GHRH analog
- A synthetic molecule resembling growth hormone-releasing hormone, which prompts the pituitary to release growth hormone rather than supplying growth hormone directly. Tesamorelin and sermorelin are both of this type.
- Lipodystrophy
- An abnormal distribution of body fat. The form tesamorelin is approved for occurs in people with HIV, and it is the population in which the drug's visceral-fat evidence was collected.
- Comparative claim
- A claim that one option beats another — for example that one route of administration is absorbed better. It requires a study that compared them; a claim about a single product cannot establish it.
Compare
Others selling what Nova sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
- Belle HealthAlso sells Sermorelin · 3 of 3 claims match the trials
- Pallas HealthAlso sells NAD+ (nicotinamide adenine dinucleotide) · 4 of 4 claims match the trials
- ShedAlso sells Sermorelin · 4 of 6 claims match the trials
- CareBareRXAlso sells NAD+ (nicotinamide adenine dinucleotide) · 2 of 4 claims match the trials
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Nova's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- US Food and Drug Administration / US National Library of Medicine (2026). EGRIFTA SV and EGRIFTA WR (tesamorelin) labels via openFDA: "indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy", with the limitation "not indicated for weight loss management"; ClinicalTrials.gov NCT00608023, phase 3, completed, 263 participants, HIV-associated lipodystrophy (24 tesamorelin studies in total). openFDA drug label API / ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT00608023
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans; no published comparison of injected NAD+ against any other route. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; ClinicalTrials.gov intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.